Lantheus LNTH
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Lantheus (LNTH) Business Model and Operations Summary
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Key Insights
Lantheus (LNTH) Core Market Data and Business Metrics
Latest Closing Price
$97.93Market Cap
$6.70 BillionPrice-Earnings Ratio
22.46Total Outstanding Shares
68.48 Million SharesTotal Employees
808Dividend
No dividendIPO Date
June 25, 2015SIC Description
In Vitro & In Vivo Diagnostic SubstancesPrimary Exchange
NASDAQHeadquarters
331 Treble Cove Road, North Billerica, MA, 01862
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $-118.54 Million |
| Exchange Gains/Losses | $-998,000 |
| Net Cash Flow From Investing Activities | $-226.01 Million |
| Net Cash Flow From Operating Activities | $544.75 Million |
| Net Cash Flow, Continuing | $200.20 Million |
| Net Cash Flow From Investing Activities, Continuing | $-226.01 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Costs And Expenses | $1.10 Billion |
| Income Tax Expense/Benefit | $118.53 Million |
| Revenues | $1.53 Billion |
| Income Tax Expense/Benefit, Deferred | $-30.03 Million |
| Benefits Costs and Expenses | $1.10 Billion |
| Income Tax Expense/Benefit, Current | $148.56 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $311.86 Million |
| Comprehensive Income/Loss | $311.86 Million |
| Comprehensive Income/Loss Attributable To Parent | $311.86 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-578,000 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $651.80 Million |
| Wages | $48.26 Million |
| Liabilities And Equity | $1.98 Billion |
| Equity | $1.09 Billion |
| Other Non-current Assets | $315.15 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||